Brief: 60 Degrees Pharma Announces IRB Approval Of Clinical Study Of Tafenoquine For Treatment Of Babesiosis
09/07/2024 12:17
July 9 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* 60 DEGREES PHARMA ANNOUNCES IRB APPROVAL OF CLINICAL STUDY
OF
TAFENOQUINE FOR TREATMENT OF BABESIOSIS IN IMMUNOCOMPROMISED
PATIENTS WITH PERSISTENT BABESIA MICROTI DESPITE PRIOR TREATMENT
* 60 DEGREES PHARMACEUTICALS - PLANS TO FILE A NEW DRUG
APPLICATION WITH FDA IN Q2 OF 2026 FOR A SUPPLEMENTAL INDICATION
FOR TAFENOQUINE IN BABESIOSIS
Source text for Eikon: ID:nGNX1h44PH
Further company coverage: SXTP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM